BriaCell Reports "Late-Breaker" Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

GlobeNewswire
2025.04.30 12:33

費城和加拿大不列顛哥倫比亞省温哥華，2025 年 4 月 30 日（GLOBE NEWSWIRE）—— BriaCell Therapeutics Corp.（納斯達克：BCTX，BCTXW，BCTXZ）（多倫多證券交易所：BCT）（“BriaCell” 或 “公司”），一家處於臨牀階段的生物技術公司，致力於開發新型免疫療法以改變癌症治療，正在

Source: GlobeNewswire The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.